Loading clinical trials...
Loading clinical trials...
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectivene...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Otsuka Canada Pharmaceutical Inc.
Collaborators
NCT06894212 · Schizophrenia
NCT07540338 · Bipolar I Disorder
NCT07494305 · Bipolar I Disorder
NCT06003036 · Schizophrenia, Schizoaffective Disorder
NCT04226898 · Schizophrenia, Schizoaffective Disorder
Ottawa Hospital, Civic Campus
Ottawa, Ontario
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions